Andere talen Nuwellis, Inc.

Aandelen

NUWE

US67113Y4052

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,206 ^USD	+54,89%		-28,72%	-64,54%

02/05	Nuwellis, Inc. USPTO ontvangt kennisgeving van patenttoelating voor innovatieve pediatrische CRRT-technologie	CI
29/04	NUWELLIS, INC. : Maxim herziet opinie en gaat over naar Neutraal	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02/05
Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02/05
Nuwellis Announces Closing of $2.7 Million Public Offering	01/05
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024	30/04
Nuwellis Announces Pricing of $2.7 Million Public Offering	26/04
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09/04
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09/04
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference	07/03
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days	07/03
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	06/03
Earnings Flash (NUWE) NUWELLIS Reports Q4 Revenue $2.6M	05/03
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results	05/03
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	27/02
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™	22/02
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/02
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference	20/02
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload	06/02
Certain Warrants of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01
Certain Stock Options of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01
Certain Common Stock of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nuwellis, Inc.

Aandelen

NUWE

US67113Y4052

Andere talen

Filters